Twenty years ago, Pfizer Inc. didn’t sell any drugs treating cancer. Now, it sells 17, including four that were approved in the U.S. at the end of last year, more than any other pharmaceutical company. The new lineup is projected to generate $8.3 billion in sales this year, according to EvaluatePharma. For the first time, Pfizer in 2019...
Pfizer has said it will sell more of its oncology products than primary care medicines in 2019 and EvaluatePharma expects the products to help generate sales of $8.3bn. The company is also looking at ways to expand into new markets such as China, where there are a growing number of patients with cancer who have been treated by outside companies.